Cadherin 6 drives epithelial-mesenchymal transition and oxaliplatin resistance in gastric cancer via transforming growth factor-β/Smad signaling axis

Figure 1 Cadherin 6 overexpression in gastric cancer promotes cell migration, invasion, and proliferation and predicts poor prognosis. A: Results of wound healing assays showing that at 24 hours and 48 hours, the scratch closure area in the cadherin 6 (CDH6)-overexpression group was significantly larger than that in the control group (P < 0.001); B: Transwell assays demonstrating that CDH6 promotes migration and invasion (P < 0.01) of HGC-27 cells; C: Cell counting kit-8 assays revealing that CDH6 overexpression enhances cell proliferation (P < 0.01); D: Flow cytometry showing significantly lower proportions of apoptotic cells in the CDH6-overexpression group compared to the control group, suggesting that CDH6 overexpression suppresses apoptosis (P < 0.001); E: Survival analysis of CDH6 in gastric cancer patients from Kaplan-Meier plotter (https://kmplot.com/). Overall survival, hazard ratio (HR) = 1.37, 95% confidence interval (CI): 1.15-1.62 (P < 0.0001); F: Post-progression survival, HR = 1.58, 95%CI: 1.27-1.98 (P < 0.0001); G: First progression, HR = 1.49, 95%CI: 1.22-1.83, P < 0.0001. ^aP < 0.05, ^bP < 0.01, and ^cP < 0.001. OE-CDH6: Cadherin 6-overexpression; HR: Hazard ratio.